Search company, investor...

Panacos Pharmaceuticals

panacos.com

Founded Year

1999

Stage

Unattributed VC - II | Alive

Total Raised

$51.55M

Last Raised

$10M | 15 yrs ago

About Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

Headquarters Location

134 Coolidge Avenue

Watertown, Massachusetts, 02472,

United States

617-926-1551

Missing: Panacos Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Panacos Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Panacos Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Panacos Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Panacos Pharmaceuticals Patents

Panacos Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/24/2004

5/26/2009

Molecular biology, HIV/AIDS, Transcription factors, G protein coupled receptors, Clusters of differentiation

Grant

Application Date

5/24/2004

Grant Date

5/26/2009

Title

Related Topics

Molecular biology, HIV/AIDS, Transcription factors, G protein coupled receptors, Clusters of differentiation

Status

Grant

Panacos Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Panacos Pharmaceuticals founded?

    Panacos Pharmaceuticals was founded in 1999.

  • Where is Panacos Pharmaceuticals's headquarters?

    Panacos Pharmaceuticals's headquarters is located at 134 Coolidge Avenue, Watertown.

  • What is Panacos Pharmaceuticals's latest funding round?

    Panacos Pharmaceuticals's latest funding round is Unattributed VC - II.

  • How much did Panacos Pharmaceuticals raise?

    Panacos Pharmaceuticals raised a total of $51.55M.

  • Who are the investors of Panacos Pharmaceuticals?

    Investors of Panacos Pharmaceuticals include Hercules Capital, New England Partners, Pappas Ventures, William Harris Investors, Lakeview Capital and 11 more.

  • Who are Panacos Pharmaceuticals's competitors?

    Competitors of Panacos Pharmaceuticals include Humanetics, CoImmune, Hydra Biosciences, Profectus BioSciences, OyaGen, Tobira Therapeutics, Selecta Biosciences, Anacor Pharmaceuticals, Keystone Nano, iPierian and 19 more.

Compare Panacos Pharmaceuticals to Competitors

P
Profectus BioSciences

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

K
Koronis Pharmaceuticals

Koronis Pharma develops antiviral therapeutics based on Viral Decay Acceleration, which exploits the strength of a virus to target its collapse.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

V
Velbionanotechnology

Velbionanotech is designing drugs for various diseases such as Heart Disease, kidney stones, AIDS, Cancer, cosmetic generic products using a short fragment of DNA as a new type of drugs. These drugs are assembled in Nanochips and as nano particals for delivering in human body, which are affective in curing the sick/diseased and healing the injured. nVBN are working into New gene therapy procedures, DNA-based sensors, and other medical applications by using a new method developed to initiate and control chemical reactions on DNA strands. On the other hand silicon-based nanochips with itching and self-assembling techniques used to deliver drugs on the diseased molecules. The company are designing bionano products for the treatment of various diseases for Kidney stones,Gallbladder,Liver, Lungs,Heart etc mixing biology with traditional machinery. VBN Nanomedicine prepared for Heart disease, Galbladder, Liver, Kidney stones will have no side effect and it is safe to use since it is herbal. nn

O
Opal Therapeutics

Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.